Furmonertinib mesylate is under clinical development by Shanghai Allist Pharmaceuticals and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II drugs for Lung Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Furmonertinib mesylate LoA Report. Buy the report here.
Recommended Buyer's Guides
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Furmonertinib mesylate overview
Alflutinib mesylate (Ivesa, Furmonertinib Mesilate) acts as an anti-cancer agent. It is formulated as tablets for oral route of administration. Ivesa is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive EGFR T790M mutation.
Alflutinib mesylate (AST-2818) is under development for the treatment of lung adenocarcinoma and non-small cell lung cancer (NSCLC). The drug candidate is administered through the oral route. It is a third-generation EGFR inhibitor T790M drug-resistant candidate which acts by targeting epidermal growth factor receptor (EGFR) mutation selective tyrosine kinase.
Shanghai Allist Pharmaceuticals overview
Shanghai Allist Pharmaceuticals (Allist Pharmaceuticals) is a China-based company focusing on the field of tumor treatment. The Company has built a research and development pipeline in the field of small molecule targeted drugs for non-small cell lung cancer. Allist Pharmaceuticals is an innovative pharmaceutical company, that discovers, manufactures and commercializes innovative medicines. Allist Pharmaceuticals is headquartered in Shanghai, China.
For a complete picture of Furmonertinib mesylate’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
